Implications of the HELIX trial for treating infants with hypoxic-ischaemic encephalopathy in low-to-middle-income countries

Perinatal hypoxia-ischaemia (HI) is the single most common trigger of perinatal brain injury, and contributes to over 2 million deaths worldwide each year, of which about 96% were from low/middle-income countries (LMICs).1 2 In high-income countries (HICs), there is compelling evidence that therapeutic hypothermia for infants with HI encephalopathy (HIE) reduces grey and white matter lesions3 4 and improves survival without disability.5–7 In view of the differing populations, risks and medical systems, it cannot be assumed that even such a simple and low-cost treatment would be suitable for LMICs.8 Supporting this concern, the HELIX Study, a large, well-designed and executed randomised controlled trial of therapeutic hypothermia for HIE in LMICs, found that treatment did not reduce the combined outcome of death or disability at 18 months of age and increased mortality.9...

Source: Archives of Disease in Childhood - Fetal and Neonatal Edition - December 15, 2022 Category: Perinatology & Neonatology Authors: Davidson, J. O., Battin, M. R., Gunn, A. J. Tags: Viewpoint Source Type: research